• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Canadian evidence-based guideline for the first-line treatment of chronic lymphocytic leukemia.加拿大慢性淋巴细胞白血病一线治疗的循证指南。
Curr Oncol. 2018 Oct;25(5):e461-e474. doi: 10.3747/co.25.4092. Epub 2018 Oct 31.
2
Canadian evidence-based guideline for frontline treatment of chronic lymphocytic leukemia: 2022 update.《加拿大慢性淋巴细胞白血病一线治疗循证指南:2022年更新》
Leuk Res. 2023 Feb;125:107016. doi: 10.1016/j.leukres.2023.107016. Epub 2023 Jan 5.
3
A Canadian evidence-based guideline for the first-line treatment of follicular lymphoma: joint consensus of the Lymphoma Canada Scientific Advisory Board.《加拿大滤泡性淋巴瘤一线治疗循证指南:加拿大淋巴瘤科学咨询委员会联合共识》
Clin Lymphoma Myeloma Leuk. 2015 Feb;15(2):59-74. doi: 10.1016/j.clml.2014.07.015. Epub 2014 Aug 2.
4
Canadian evidence-based guideline for treatment of relapsed/refractory chronic lymphocytic leukemia.加拿大复发/难治性慢性淋巴细胞白血病治疗的循证指南。
Leuk Res. 2023 Oct;133:107372. doi: 10.1016/j.leukres.2023.107372. Epub 2023 Aug 19.
5
Diagnosis, treatment and supportive management of chronic lymphocytic leukemia: recommendations of the Dutch HOVON CLL working group.慢性淋巴细胞白血病的诊断、治疗及支持性管理:荷兰HOVON慢性淋巴细胞白血病工作组的建议
Leuk Lymphoma. 2022 Oct;63(10):2276-2289. doi: 10.1080/10428194.2022.2084731. Epub 2022 Jun 23.
6
A canadian perspective on the first-line treatment of chronic lymphocytic leukemia.加拿大人对慢性淋巴细胞白血病一线治疗的观点。
Clin Lymphoma Myeloma Leuk. 2015 Jun;15(6):303-13. doi: 10.1016/j.clml.2015.03.002. Epub 2015 Mar 26.
7
What Is Optimal Front-Line Therapy for Chronic Lymphocytic Leukemia in 2017?2017年慢性淋巴细胞白血病的最佳一线治疗方案是什么?
Curr Treat Options Oncol. 2017 Feb;18(2):12. doi: 10.1007/s11864-017-0450-8.
8
Evidence-Based Management of Chronic Lymphocytic Leukemia: Consensus Statements from the Gulf Region.基于证据的慢性淋巴细胞白血病管理:海湾地区的共识声明。
Acta Haematol. 2024;147(3):260-279. doi: 10.1159/000531675. Epub 2023 Sep 26.
9
Chronic lymphocytic leukemia: a clinical review.慢性淋巴细胞白血病:临床综述。
JAMA. 2014 Dec 3;312(21):2265-76. doi: 10.1001/jama.2014.14553.
10
Update of the Grupo Español de Leucemia Linfocítica Crónica clinical guidelines of the management of chronic lymphocytic leukemia.西班牙慢性淋巴细胞白血病临床指南:慢性淋巴细胞白血病管理的更新
Med Clin (Barc). 2017 Apr 21;148(8):381.e1-381.e9. doi: 10.1016/j.medcli.2016.12.030. Epub 2017 Feb 22.

引用本文的文献

1
An approach to anxiety during watch-and-wait for Chronic Lymphocytic Leukemia: Monitor and move on.慢性淋巴细胞白血病观察等待期间焦虑症的应对方法:监测并继续前行。
Can Oncol Nurs J. 2023 Nov 1;33(4):475-479. eCollection 2023 Fall.
2
[Not Available].[无可用内容]
Can Oncol Nurs J. 2023 Nov 1;33(4):480-485. eCollection 2023 Fall.
3
Clinical Outcomes in a Large Canadian Centralized CLL Clinic Based on Treatment and Molecular Factors over a Decade.基于治疗和分子因素的加拿大大型集中性 CLL 临床十年预后分析。
Curr Oncol. 2023 Jul 5;30(7):6411-6431. doi: 10.3390/curroncol30070472.
4
Expert consensus on the management of chronic lymphocytic leukaemia in Asia.亚洲慢性淋巴细胞白血病管理专家共识。
Clin Exp Med. 2023 Oct;23(6):2895-2907. doi: 10.1007/s10238-023-01007-2. Epub 2023 Feb 16.
5
Examining Treatment Patterns and Real-World Outcomes in Chronic Lymphocytic Leukemia Using Administrative Data in Ontario.利用安大略省的行政数据研究慢性淋巴细胞白血病的治疗模式和真实世界结局。
Curr Oncol. 2021 Nov 19;28(6):4832-4844. doi: 10.3390/curroncol28060408.
6
Frontline Treatment of the Young, Fit Patient with CLL: A Canadian Perspective.年轻、健康的 CLL 患者的一线治疗:加拿大视角。
Curr Oncol. 2021 Sep 30;28(5):3825-3835. doi: 10.3390/curroncol28050326.
7
Updates from the American Society of Hematology 2019 annual meeting: practice-changing studies in treatment-naïve chronic lymphocytic leukemia.美国血液学会 2019 年年会更新:治疗初治慢性淋巴细胞白血病的具有改变实践意义的研究。
Curr Oncol. 2020 Apr;27(2):e231-e245. doi: 10.3747/co.27.6291. Epub 2020 May 1.

本文引用的文献

1
Rituximab plus bendamustine or chlorambucil for chronic lymphocytic leukemia: primary analysis of the randomized, open-label MABLE study.利妥昔单抗联合苯达莫司汀或苯丁酸氮芥治疗慢性淋巴细胞白血病:随机、开放标签 MABLE 研究的主要分析。
Haematologica. 2018 Apr;103(4):698-706. doi: 10.3324/haematol.2017.170480. Epub 2018 Feb 1.
2
Long-term Follow-up of Treatment with Ibrutinib and Rituximab in Patients with High-Risk Chronic Lymphocytic Leukemia.伊布替尼和利妥昔单抗治疗高危慢性淋巴细胞白血病患者的长期随访
Clin Cancer Res. 2017 May 1;23(9):2154-2158. doi: 10.1158/1078-0432.CCR-16-1948. Epub 2016 Oct 19.
3
Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood. 1975;46(2):219-234.赖·KR、萨维茨基·A、克朗凯特·EP、查纳纳·AD、利维·RN、帕斯特纳克·BS。慢性淋巴细胞白血病的临床分期。《血液》。1975年;46(2):219 - 234。
Blood. 2016 Oct 27;128(17):2109. doi: 10.1182/blood-2016-08-737650.
4
Rituximab in Lymphoma and Chronic Lymphocytic Leukaemia: A Practice Guideline.利妥昔单抗治疗淋巴瘤和慢性淋巴细胞白血病:实践指南
Clin Oncol (R Coll Radiol). 2017 Jan;29(1):e13-e28. doi: 10.1016/j.clon.2016.09.004. Epub 2016 Oct 14.
5
The CLL-IPI applied in a population-based cohort.CLL-IPI应用于一项基于人群的队列研究。
Blood. 2016 Oct 27;128(17):2181-2183. doi: 10.1182/blood-2016-07-724740. Epub 2016 Sep 7.
6
Ofatumumab monotherapy as a consolidation strategy in patients with previously untreated chronic lymphocytic leukaemia: a phase 2 trial.奥法木单抗单药治疗作为初治慢性淋巴细胞白血病患者巩固治疗策略的2期试验
Lancet Haematol. 2016 Sep;3(9):e407-14. doi: 10.1016/S2352-3026(16)30064-3. Epub 2016 Aug 1.
7
Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients.新诊断患者中慢性淋巴细胞白血病国际预后指数(CLL-IPI)的验证及其与MD安德森癌症中心预后指数的比较。
Blood. 2016 Oct 20;128(16):2093-2095. doi: 10.1182/blood-2016-07-728261. Epub 2016 Aug 22.
8
Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial.利妥昔单抗维持治疗与单纯观察在一线或二线含利妥昔单抗化疗免疫治疗有反应的慢性淋巴细胞白血病患者中的比较:AGMT CLL-8a Mabtenance随机试验的最终结果
Lancet Haematol. 2016 Jul;3(7):e317-29. doi: 10.1016/S2352-3026(16)30045-X. Epub 2016 Jun 16.
9
Complex karyotypes and KRAS and POT1 mutations impact outcome in CLL after chlorambucil-based chemotherapy or chemoimmunotherapy.基于苯丁酸氮芥的化疗或化疗免疫治疗后,复杂核型和 KRAS 及 POT1 突变影响 CLL 的预后。
Blood. 2016 Jul 21;128(3):395-404. doi: 10.1182/blood-2016-01-691550. Epub 2016 May 25.
10
First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial.一线苯达莫司汀和利妥昔单抗联合化疗与氟达拉滨、环磷酰胺和利妥昔单抗治疗晚期慢性淋巴细胞白血病(CLL10)患者:一项国际、开放标签、随机、III 期、非劣效性临床试验。
Lancet Oncol. 2016 Jul;17(7):928-942. doi: 10.1016/S1470-2045(16)30051-1. Epub 2016 May 20.

加拿大慢性淋巴细胞白血病一线治疗的循证指南。

Canadian evidence-based guideline for the first-line treatment of chronic lymphocytic leukemia.

作者信息

Owen C, Gerrie A S, Banerji V, Assouline S, Chen C, Robinson K S, Lye E, Fraser G

机构信息

Division of Hematology and Hematological Malignancies, Foothills Medical Centre, Calgary, AB.

Division of Medical Oncology, University of British Columbia and BC Cancer, Vancouver, BC.

出版信息

Curr Oncol. 2018 Oct;25(5):e461-e474. doi: 10.3747/co.25.4092. Epub 2018 Oct 31.

DOI:10.3747/co.25.4092
PMID:30464698
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6209557/
Abstract

Chronic lymphocytic leukemia (cll) is the most common adult leukemia in North America. In Canada, no unified national guideline exists for the front-line treatment of cll; provincial guidelines vary and are largely based on funding. A group of clinical experts from across Canada developed a national evidence-based treatment guideline to provide health care professionals with clear guidance on the first-line management of cll. Consensus recommendations based on available evidence are presented for the first-line treatment of cll.

摘要

慢性淋巴细胞白血病(CLL)是北美最常见的成人白血病。在加拿大,不存在针对CLL一线治疗的统一国家指南;各省的指南各不相同,且很大程度上基于资金情况。一群来自加拿大各地的临床专家制定了一项基于证据的国家治疗指南,为医疗保健专业人员提供关于CLL一线管理的明确指导。本文针对CLL的一线治疗提出了基于现有证据的共识性建议。